Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1758834 | 0.80 | ACHE (0.50) | ALDH1A1KDM4EMAPTMAPK1GAA | |
| SCHEMBL1758614 | 0.80 | ALDH1A1 (0.56) | ALDH1A1KDM4EUSP2MAPTMAPK1 | |
| SCHEMBL9347449 | 0.79 | TSHR (0.51) | ALDH1A1GFERMAPTMAPK1NPSR1 | |
| SCHEMBL1758548 | 0.79 | KMT2A (0.57) | ALDH1A1KDM4EMAPTMAPK1NPSR1 | |
| SCHEMBL19677081 | 0.79 | HTT (0.48) | ALDH1A1KDM4EUSP2PYGLMAPT | |
| SCHEMBL28617698 | 0.78 | HTT (0.47) | ALDH1A1KDM4EMAPTMAPK1NPSR1 | |
| SCHEMBL3241465 | 0.77 | BRD4 (0.54) | ALDH1A1KDM4EUSP2RAD52GFER | |
| SCHEMBL11344842 | 0.77 | MAPT (0.52) | ALDH1A1KDM4EUSP2RAD52GFER | |
| SCHEMBL25557097 | 0.77 | ALDH1A1 (0.48) | ALDH1A1KDM4EUSP2RAD52GFER | |
| SCHEMBL11029210 | 0.76 | KDM4E (0.44) | ALDH1A1KDM4EMAPTMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866307-A1 | SYNTHESIS OF PYRROLOQUINOLINE QUINONE (PQQ) | CLF Medical Technology Acceleration Program, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| US-20070072894-A1 | Synthesis of pyrroloquinoline quinone (PQQ) | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. | 2007-03-29 | — | — | US | claimed |
| WO-2006102642-A1 | SYNTHESIS OF PYRROLOQUINOLINE QUINONE (PQQ) | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| EP-2918585-B1 | PYRROLOQUINOLINE QUINONE DISODIUM SALT CRYSTAL | ZHUCHENG HAOTIAN PHARM CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| US-9695164-B2 | Crystalline forms of pyrroloquinoline quinone disodium salt | ZHUCHENG HAOTIAN PHARM CO., LTD. (CN) | 2017-07-04 | — | — | US | disclosed |
| US-20150291583-A1 | CRYSTALLINE FORMS OF PYRROLOQUINOLINE QUINONE DISODIUM SALT | ZHUCHENG HAOTIAN PHARM CO., LTD. (CN) | 2015-10-15 | — | — | US | disclosed |
| EP-2918585-A1 | PYRROLOQUINOLINE QUINONE DISODIUM SALT CRYSTAL | Zhucheng Haotian Pharm Co., Ltd. (CN) | 2015-09-16 | — | — | EP | disclosed |
| US-20140178316-A1 | SKIN TREATMENTS CONTAINING PYRROLOQUINOLINE QUINONE (PQQ) ESTERS AND METHODS OF PREPARATION AND USE THEREOF | US COSMECEUTECHS, LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140178316-A1 | SKIN TREATMENTS CONTAINING PYRROLOQUINOLINE QUINONE (PQQ) ESTERS AND METHODS OF PREPARATION AND USE THEREOF | US COSMECEUTECHS, LLC (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2012170378-A1 | SKIN TREATMENTS CONTAINING PYRROLOQUINOLINE QUININE (PQQ) ESTERS AND METHODS OF PREPARATION AND USE THEREOF | US COSMECEU TECHS, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| CN-101193888-A | Synthesis method of pyrroloquinoline quinone (PQQ) | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM INC (US) | 2008-06-04 | — | — | CN | disclosed |
| EP-1866307-A1 | SYNTHESIS OF PYRROLOQUINOLINE QUINONE (PQQ) | CLF Medical Technology Acceleration Program, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070072894-A1 | Synthesis of pyrroloquinoline quinone (PQQ) | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072894-A1 | Synthesis of pyrroloquinoline quinone (PQQ) | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072894-A1 | Synthesis of pyrroloquinoline quinone (PQQ) | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2006102642-A1 | SYNTHESIS OF PYRROLOQUINOLINE QUINONE (PQQ) | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291583-A1 | CRYSTALLINE FORMS OF PYRROLOQUINOLINE QUINONE DISODIUM SALT | SFPQ, RECQL, AQP1 | ALDH1A1 1085/4885KDM4E 2287/4885USP2 3494/4885 |
| US-20140178316-A1 | SKIN TREATMENTS CONTAINING PYRROLOQUINOLINE QUINONE (PQQ) ESTERS AND METHODS OF PREPARATION AND USE THEREOF | POLQ, NQO1, CUTA | ALDH1A1 1227/4885KDM4E 221/4885USP2 911/4885 |
| US-20070072894-A1 | Synthesis of pyrroloquinoline quinone (PQQ) | QPCT, SYNCRIP, SFPQ | ALDH1A1 3446/4885KDM4E 730/4885USP2 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.